Elite Pharmaceuticals Cuts Stability Reporting Time by 50% for FDA Submissions

Elite Pharmaceuticals Inc. is a specialty pharmaceutical company known for its expertise in developing abuse-deterrent formulations and controlled-release technologies. With a diverse pipeline of products requiring extensive long-term and accelerated stability studies to support regulatory submissions, Elite needed a stability management platform that could handle complex study designs while maintaining full 21 CFR Part 11 compliance.

AmpleLogic's Advanced Stability Management System was deployed to manage Elite's entire stability program. The platform supported study design with configurable protocols for ICH Q1A-compliant studies, automatic scheduling of pull points based on study initiation dates, and integrated stability chambers monitoring with real-time temperature and humidity data. Sample tracking ensured no stability samples were missed, and automated pull-point reminders kept testing on schedule.

Laboratory results were entered directly into the stability module, with automatic trend analysis comparing results against acceptance criteria at each time point. Statistical trending tools identified potential stability failures early in the study timeline, allowing the regulatory team to proactively address concerns before submission deadlines. Comprehensive stability reports were generated in regulatory submission format, dramatically reducing the time required to compile and review stability data.

Elite Pharmaceuticals achieved a 50% reduction in stability reporting cycle times, enabling faster NDA and ANDA submissions. The elimination of spreadsheet-based stability tracking — which had been prone to formula errors and manual update oversights — improved data reliability and removed a significant source of regulatory risk. The platform became central to Elite's regulatory strategy, supporting multiple successful FDA submissions.